SIWA318H: A new antibody against pancreatic cancer

A preclinical study highlights the potential of SIWA318H, an antibody targeting advanced glycation end-products, in the fight against pancreatic cancer.

The dark side of cellular senescence

Cellular senescence is a fundamental biological process that imposes a permanent growth arrest on cells, playing a crucial role in preventing tumour growth. This mechanism has traditionally been considered an ally in the fight against cancer because it prevents damaged cells from proliferating uncontrollably. However, recent research has revealed a dark side of cellular senescence, highlighting how senescent cells can have a negative impact on anti-cancer therapy and the immune response, promoting cancer progression. Particularly in pancreatic ductal carcinoma, one of the most lethal forms of cancer, the contribution of senescent cells to the tumour environment is significant, hindering immunotherapy and drug delivery. A new study examines in detail the potential of the antibody SIWA318H, a specific agent for cellular senescence, in the targeted elimination of senescent cells in pancreatic tumours.

The role of CML as a biomarker for senescent cells

One of the main markers used to identify senescent cells is NƐ-carboxymethyl lysine (CML), an advanced glycation product. This molecule is known to accumulate significantly in senescent cells and is a reliable indicator of this cell state. The binding of SIWA318H to CML underlines its effectiveness in recognising and targeting senescent cells within the tumour. This specific binding allows the antibody to selectively detect senescent cells in the tumour context, opening new perspectives for their targeted targeting.

The removal of senescent cells

This study highlights the crucial role of senescent cells in the tumour environment of pancreatic ductal adenocarcinoma (PDAC). Cell senescence contributes to the creation of a strongly immunosuppressive tumour environment. This environment is characterised by the presence of senescent fibroblasts that promote a desmoplastic reaction, causing thickening and stiffening of the extracellular matrix (ECM). This process greatly hinders the immigration of immune system cells and the distribution of drugs within the tumour, making therapy less effective. Therefore, the use of the SIWA318H antibody could have a significant impact in the targeted removal of senescent cells within the pancreatic tumour. The ability to eliminate these cells may open new avenues in pancreatic cancer therapy by improving the immune response and drug delivery.

The efficacy of SIWA318H

The article reports promising results obtained with the use of the SIWA318H antibody. This humanised antibody shows high affinity and specificity in binding to senescent cells. Preclinical studies in mice humanised with pancreatic cell xenografts revealed that SIWA318H is able to reduce tumour growth. Furthermore, the antibody demonstrated its efficacy in antibody-dependent cell-mediated cytotoxicity (ADCC) against pancreatic cancer cells. These results demonstrate the promising anti-tumour activity of SIWA318H and suggest that it could be an important therapeutic tool in the treatment of PDAC.

SIWA318H, a hope for pancreatic ductal adenocarcinoma (PDAC)

The article highlights the revolutionary potential of the SIWA318H antibody in the treatment of PDAC. The ability to target senescent cells could represent a breakthrough in optimising the tumour environment, making the tumour more susceptible to immunotherapy and drug efficacy. Further research and clinical trials are needed to confirm the efficacy and safety of SIWA318H in the treatment of pancreatic cancer. These preliminary results open new perspectives in the fight against this devastating form of cancer, providing a solid basis for further scientific and clinical exploration.

  1. Rossi GR, Jensen A, Ng S, Yin Z, Li A, Misra A, Von Hoff DD, Gruber L, Gruber M, Han H. Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer. Sci Rep. 2023 Oct 7;13(1):16953. doi: 10.1038/s41598-023-44211-6. PMID: 37805542; PMCID: PMC10560265.